Metsera Seeks $289M Raise, $1.78B Valuation in IPO

Pictured: Man prepares his GLP-1 injection

Pictured: Man prepares his GLP-1 injection

iStock, imyskin

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera is moving fast. Nine months post-launch and two weeks after announcing its plans for an IPO, the New York City–based weight-loss company said Monday that it is seeking a $1.78 billion valuation and a $250 million raise. Metsera is offering 17.19 million shares priced between $15 and $17.

The raise could be as high as $289.1 million if the underwriters exercise their option to purchase additional shares.

Those proceeds will go toward a Phase III trial for Metsera’s lead molecule, MET-097i, an injectable, long-acting GLP-1 receptor agonist. In early January, the company reported Phase II data showing as much as 20% weight loss in some patients.

Metsera exited stealth in April 2024 with $290 million in funding, followed by an additional $215 million raised a few months later.

The substantial financing and large IPO targets set by Metsera are indicative of the swell of money entering the obesity treatment field, with a total estimated valuation of $100 - $150 billion per year by 2030. The lead technology driving MET-097i is its long half-life, according to Metsera, which in Phase II trials increased in concentration over a 12-week period, potentially allowing for less frequent injections.

The IPO market for GLP-1 agonists has gained heat over the last two years. Raises from similar companies reached into the neighborhood of Metsera’s hoped-for $289.1 million. In September 2024 MBX Biosciences raised about $188 million at $16 per share (currently trading at about $10), and in October, BioAge Labs raised $283 million in an IPO at $18 per share (currently trading at about $5 per share after losing 75% of its value in December). Earlier in the year, Fractyl Health raised approximately $110 million to fund a GLP-1 gene therapy. Carmot Therapeutics, yet another GLP-1 developer, had plans to go public before being bought out by Roche for $2.7 billion.

Dan Samorodnitsk has a decade of experience covering biotech, genetics and medicine at BioSpace, Drug Discovery News and Massive Science. His writing has appeared in outlets such as Quanta, STAT, GROW and many others. You can follow him on LinkedIn.
MORE ON THIS TOPIC